Publication:


abstract

BACKGROUND:

natural killer (NK) cells likely contribute to outcome of acute hepatitis C virus (HCV) infection and interferon (IFN)-induced control of chronic HCV infection. We previously observed IFN-αR and NKp30 expression associated with IFN-α-dependent NK cell activity.

METHODS:

Here, we examined CD16(+)56(-), CD16(+)56(+), and CD16(-)56(+) NK cell subset IFN-αR and NKp30 expression in relation to magnitude of HCV genotype 1 decrease during pegylated IFN-α plus ribavirin therapy.

RESULTS:

We observed greater baseline IFN-αR and NKp30 expression on CD16(+)56(+) and CD16(-)56(+) NK subsets in HCV-infected patients than in healthy control subjects. Baseline CD16(+)56(-) NK IFN-αR expression was associated with IFN-α-induced pSTAT1, and both were associated with magnitude of HCV decrease during pegylated IFN-α plus ribavirin therapy. Baseline CD16(+)56(-) NK IFN-αR expression was associated with race and interleukin 28B genotype, negatively associated with aspartate aminotransferase-to platelet ratio index, and positively associated with increase in NKp30 expression after in vivo IFN-α exposure. Finally, in vitro IFN-α2a-activated NK cytolysis of HCV-infected target cells was in part dependent on NKp30, and CD16(+)56(-) NK cell IFN-αR expression correlated with cytolytic activity.

CONCLUSIONS:

IFN-αR expression on CD16(+)56(-) NK cells during chronic HCV infection may in part be Genetically determined, and level of expression regulates IFN-α signaling, which in turn may contribute to control of HCV infection.

Related Articles
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
Eur J Immunol. 2011
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
Bozzano F, Picciotto A, Costa P, Marras F, Fazio V, Hirsch I, Olive D, Moretta L, De Maria A. Eur J Immunol. 2011 Oct; 41(10):2905-14.
Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
J Med Virol. 2010
Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
Lee S, Watson MW, Flexman JP, Cheng W, Hammond T, Price P. J Med Virol. 2010 Apr; 82(4):568-74.
Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
J Immunol. 2009
Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
Gonzalez VD, Falconer K, Björkström NK, Blom KG, Weiland O, Ljunggren HG, Alaeus A, Sandberg JK. J Immunol. 2009 Nov 15; 183(10):6612-8. Epub 2009 Oct 21.
Review The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus.
Cell Immunol. 2010
Review The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus.
Salem ML, El-Demellawy M, El-Azm AR. Cell Immunol. 2010; 262(2):96-104. Epub 2010 Mar 6.
Review Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).
Clin Ter. 2006
Review Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).
Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R. Clin Ter. 2006 Sep-Oct; 157(5):457-68.